Therapeutic Area

Autoimmune Disease

Therapeutic area intelligence for Autoimmune Disease with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 3

Companies

AbbVie →

Regeneron →

Roche →

Assets

Dermatology →

dupilumab →

ENSPRYNG →

Recent signals(3)

ClinicalJune 20, 2026

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

A study is underway to evaluate the efficacy and safety of dupilumab in treating bullous pemphigoid, an autoimmune blistering disease.

RegulatoryJune 17, 2026

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.

ClinicalJune 17, 2026

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Autoimmune Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.